Tuesday, October 4, 2022


Biotechnology News Magazine

VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to evaluate apraglutide, a next-generation, long-acting GLP-2 analog, in a Phase 2 clinical trial called STARGAZE (Study of Apraglutide in Graft-Versus-Host Disease), for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD).

Apraglutide previously received orphan drug designation by the FDA for the prevention of aGVHD in June.

“Acute graft-versus-host disease typically emerges within the first 100 days after a hematopoietic stem cell transplant and is associated with a high mortality rate,” said Omar Khwaja, M.D., Ph.D., Chief Medical Officer of VectivBio. “We have demonstrated promising preclinical results with apraglutide as a novel approach to treating acute graft-versus-host disease, showing a significant reduction in mortality after treatment with apraglutide in mouse models. We are encouraged by this preliminary data and look forward to dosing the first patient in a Phase 2 clinical trial in 1Q 2022.”

“Despite significant advances in managing steroid-refractory graft-versus-host disease, there still remains a high unmet need to develop non-immunosuppressive treatment options specifically targeting the GI tract, one of the primary tissue systems damaged in acute graft-versus-host disease,” said Prof. Robert Zeiser, Head of Tumor Immunology and Immune Modulation at the University Medical Center Freiburg. “I believe that apraglutide represents a potentially transformative new therapeutic option for acute graft-versus-host disease patients thanks to its GLP-2 receptor mediated effects on protecting and regenerating Paneth cells and intestinal stem cells.”

STARGAZE, a Phase 2, randomized, double-blind study, will assess the safety, tolerability, pharmacokinetic profile and efficacy of apraglutide in patients with steroid-refractory aGVHD. Dosing of the first patient is expected in 1Q 2022. Interim data read out is anticipated for 2H 2022.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine